VOLUME 9 (2018)
View Archive »
About The Cover
The cover for issue 100 of Oncotarget features Figure 9, "Proposed model for the induction of PD-L1 by Hh signaling," by Chakrabarti, et al.
|
|
Table of Contents
Editorial
|
| Intermediate phenotypes underlying osteosarcoma risk |
|
https://doi.org/10.18632/oncotarget.26476
|
| 37345-37346 |
|
| UBE2N plays a pivotal role in maintaining melanoma malignancy |
|
https://doi.org/10.18632/oncotarget.26482
|
| 37347-37348 |
|
| Targeting hyaluronan accumulation in the tumor microenvironment |
|
https://doi.org/10.18632/oncotarget.26483
|
| 37349-37351 |
Priority Research Papers
|
| CDK4/6 inhibition stabilizes disease in patients with p16null nonsmall cell lung cancer and is synergistic with mTOR inhibition |
|
https://doi.org/10.18632/oncotarget.26424
|
| 37352-37366 |
Research Papers
|
| Anticlaudin4 extracellular domain antibody enhances the antitumoral effects of chemotherapeutic and antibody drugs in colorectal cancer |
|
https://doi.org/10.18632/oncotarget.26427
|
| 37367-37378 |
|
| MEKinhibitor PD184352 enhances the radiosensitizing effect of the Hsp90 inhibitor NVPAUY922: the role of cell type and drugirradiation schedule |
|
https://doi.org/10.18632/oncotarget.26436
|
| 37379-37392 |
|
| EGFR C797S EGFR T790M and EGFR sensitizing mutations in nonsmall cell lung cancer revealed by sixcolor crystal digital PCR |
|
https://doi.org/10.18632/oncotarget.26446
|
| 37393-37406 |
|
| Identification of a gene signature for different stages of breast cancer development that could be used for early diagnosis and specific therapy |
|
https://doi.org/10.18632/oncotarget.26448
|
| 37407-37420 |
|
| AntiC1inactivator treatment of glioblastoma |
|
https://doi.org/10.18632/oncotarget.26456
|
| 37421-37428 |
|
| KLHL5 knockdown increases cellular sensitivity to anticancer drugs |
|
https://doi.org/10.18632/oncotarget.26462
|
| 37429-37438 |
|
| Hedgehog signaling induces PDL1 expression and tumor cell proliferation in gastric cancer |
|
https://doi.org/10.18632/oncotarget.26473
|
| 37439-37457 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC